Last reviewed: 8 April 2026
Some people with aspergillosis are told they have cystic fibrosis (CF), or that they carry a CFTR gene variant. This can be unexpected and may raise concerns about whether this explains their symptoms or diagnosis.
This article explains how cystic fibrosis and CFTR gene variants relate to Aspergillus-related lung disease, what current research shows, and—importantly—what conclusions should not be drawn.
Contents
- Key points
- Important reassurance
- What is cystic fibrosis?
- What is a CFTR gene variant?
- How CFTR affects the lungs
- How Aspergillus behaves in the lungs
- ABPA and cystic fibrosis
- CPA and cystic fibrosis
- Modern CF treatments and Aspergillus
- Does a CFTR variant explain symptoms?
- What should patients take from this?
- When to seek medical advice
- Conclusion
- References
Key points
- Most people with aspergillosis do not have cystic fibrosis.
- Most people with cystic fibrosis do not develop ABPA or CPA.
- ABPA is linked to mucus and immune responses, not just infection.
- CFTR variants may contribute to risk in some people, but are usually only one factor.
- CPA is mainly driven by structural lung damage, not CFTR genetics.
Important reassurance
Most people with aspergillosis do not have cystic fibrosis, and most people with cystic fibrosis do not develop Aspergillus-related disease.
Although these conditions can overlap, they are usually separate. Genetic findings such as CFTR variants should be interpreted carefully and in context.
What is cystic fibrosis?
Cystic fibrosis is a genetic condition caused by changes in the CFTR gene. This gene regulates salt and water movement across cells.
When CFTR function is reduced:
- mucus becomes thick and sticky
- airways are harder to clear
- microorganisms persist more easily
This creates an environment where bacteria and fungi can accumulate over time.
What is a CFTR gene variant?
CFTR variants range from severe mutations (causing cystic fibrosis) to mild or uncertain variants.
Carriers (with one variant):
- are common in the general population
- usually have no symptoms
- may have subtle effects in some cases
These subtle effects may include reduced mucus clearance or increased susceptibility to airway inflammation.
How CFTR affects the lungs
CFTR dysfunction affects the lungs in several key ways:
- Mucus dehydration: mucus becomes thick and difficult to clear
- Impaired clearance: particles and microbes remain in the airways
- Chronic inflammation: immune responses become exaggerated
This combination creates a “retention environment” where inhaled organisms—including Aspergillus—may persist.
How Aspergillus behaves in the lungs
Aspergillus is inhaled by everyone, but its effects vary depending on the lung environment.
- Healthy lungs: spores are cleared
- Impaired clearance: spores may persist
- Sensitive immune system: allergic reactions may develop
- Damaged lungs: chronic infection may develop
This explains why Aspergillus-related disease is diverse and depends heavily on underlying lung conditions.
ABPA and cystic fibrosis
ABPA is an allergic immune reaction to Aspergillus.
It is recognised in cystic fibrosis because:
- mucus retention increases exposure to Aspergillus
- immune responses can be exaggerated
However:
- Many CF patients never develop ABPA
- Most ABPA patients do not have CF
Some studies suggest CFTR variants may increase susceptibility, but this is not consistent across all research.
Key message: ABPA and CF can overlap, but one does not imply the other.
CPA and cystic fibrosis
CPA is a chronic fungal infection that develops in structurally damaged lungs.
The most important risk factor is:
pre-existing lung damage
This includes:
- bronchiectasis
- previous tuberculosis
- COPD
Cystic fibrosis can lead to bronchiectasis, and therefore indirectly increase CPA risk.
However:
- CPA is rarely driven directly by CFTR genetics
- most CPA patients do not have CF
Key message: CPA is primarily a disease of lung structure, not genetics.
Modern CF treatments and Aspergillus
CFTR modulators (such as elexacaftor/tezacaftor/ivacaftor) have transformed CF care.
They:
- improve CFTR function
- thin mucus
- improve clearance
Studies suggest:
- reduced Aspergillus detection in some patients
- fewer ABPA exacerbations in some cases
However:
- ABPA still occurs
- existing lung damage remains
- immune responses are not fully corrected
Overall: these therapies improve risk but do not eliminate Aspergillus-related disease.
Does a CFTR variant explain symptoms?
No single factor explains complex lung disease.
Symptoms may result from:
- underlying lung disease
- infection
- inflammation
- environmental exposure
A CFTR variant may contribute, but is rarely the sole cause.
What should patients take from this?
- CF and CFTR variants can sometimes contribute
- ABPA has the strongest connection
- CPA is mainly driven by lung damage
- Most patients with aspergillosis do not have CF
When to seek medical advice
Seek advice if symptoms worsen, change, or include coughing up blood, fever, or chest pain.
Conclusion
Cystic fibrosis and CFTR gene variants can play a role in some patients with Aspergillus-related lung disease, particularly where mucus clearance is affected. However, they should not be overemphasised. In most cases, they are just one part of a broader clinical picture involving lung structure, immune response, and environmental exposure.
References
- Miller PW et al. (1996)
- Marchand E et al. (2001)
- Eaton TE et al. (2002)
- Agarwal R et al. (2012)
- Chaudhary N et al. (2012)
- Warris A et al. (2019)
- Gamaletsou MN et al. (2018)
- Kosmidis C & Denning DW (2015)
- Moldoveanu B et al. (2021)
- Malik HS et al. (2025)
- Zeng C et al. (2025)
- Bendixen MP et al. (2025)
This article is for general information and does not replace advice from your clinical team.
Latest News posts
News archive